- Home
- RLAY
as 03-28-2025 4:00pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 620.4M | IPO Year: | 2020 |
| Target Price: | $19.33 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.69 - $10.72 | Next Earning Date: | 05-01-2025 |
| Revenue: | $10,007,000 | Revenue Growth: | -60.83% |
| Revenue Growth (this year): | -64.17% | Revenue Growth (next year): | 544.28% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sanjiv | RLAY | President and CEO | Feb 11 '25 | Sell | $3.78 | 215,506 | $818,399.50 | 625,948 | |
| Bergstrom Donald A | RLAY | President, R&D | Jan 28 '25 | Sell | $4.53 | 80,450 | $362,298.11 | 516,868 | |
| Adams Brian | RLAY | Chief Legal Officer | Jan 28 '25 | Sell | $4.53 | 54,479 | $247,871.66 | 287,920 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Jan 28 '25 | Sell | $4.56 | 58,936 | $268,338.85 | 379,431 | |
| Rahmer Peter | RLAY | See remarks | Jan 28 '25 | Sell | $4.53 | 45,464 | $204,752.54 | 307,081 | |
| Patel Sanjiv | RLAY | President and CEO | Jan 21 '25 | Sell | $4.70 | 375,000 | $1,762,500.00 | 625,948 | |
| Rahmer Peter | RLAY | See remarks | Jan 2 '25 | Sell | $4.30 | 80,909 | $345,571.70 | 307,081 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
Zacks
25 days ago
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)
GlobeNewswire
a month ago
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
GuruFocus.com
a month ago
What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings
GlobeNewswire
a month ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewswire
a month ago
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
MT Newswires
2 months ago
Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing
MT Newswires
2 months ago
Relay Therapeutics Insider Sold Shares Worth $362,298, According to a Recent SEC Filing
Insider Monkey
2 months ago
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.